Press Resease

Anti-Neoplastic Agents Market - Global Industry Analysis

Anti-Neoplastic Agents Market - By Product Type (Targeted Therapy, Chemotherapy, Hormonal Therapy (Biologic Therapy), Immunotherapy, and Others), By End-Users/Application (Breast Cancer, Blood Cancer, Prostate Cancer, Gastrointestinal Cancer, Respiratory/Lung Cancer, and Other Cancers), And By Region - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 – 2026

Published Date: 09-Oct-2020 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-3024 Status : Published

Global Anti-Neoplastic Agents market, which was estimated at 110(USD Billion) in 2019 and projected to hit revenue of nearly 165.78 (USD Billion) by 2026, is set to record a CAGR of nearly 8% over 2020-2026.

Description

The global Anti-Neoplastic Agents market, which was estimated at 110(USD Billion) in 2019 and projected to hit revenue of nearly 165.78 (USD Billion) by 2026, is set to record a CAGR of nearly 8% over 2020-2026. The report offers valuation and analysis of Anti-Neoplastic Agents market on a global as well as regional level. The study offers a comprehensive assessment of the industry competition, limitations, sales estimates, avenues, current & emerging trends, and industry-validated market data. The report offers historical data from 2016 to 2019 along with a forecast from 2020 to 2026 based on value (USD Billion).

Introduction

Antineoplastic agents, also referred as cytotoxic agents, are the kind of medicines that hinder the maturation and multiplication of neoplasms. They travel into the human body and destroy the cancerous cells. These medicines are utilized for myriad kinds of cancers along with its application in surgeries, radiotherapies, and immunotherapies for many metastatic tumors. The market for antineoplastic is predicted to expand at a rapid rate with new incidences of neoplasms witnessed across the globe. The surging requirement for cost-efficient therapies for curing the neoplasms is projected to propel the growth of anti-neoplastic agents market in the foreseeable future.

Market Growth Dynamics

The growth of the market over the estimated timespan is attributed to growing cases of cancer along with demand for cost-efficient therapies. Breakthroughs in the personalized medicine domain are predicted to offer new growth avenues for the anti-neoplastic agents industry over the forecast timeline. These drugs are utilized in combination with other drug treatments in radiotherapies, surgeries, hormone therapies, and other various targeted therapies and this will drive the market trends. Nonetheless, low level of awareness pertaining to cancer symptoms in emerging economies as well as under-developed countries will pose a threat towards the expansion of the industry over the forecast timespan. Apparently, high costs of developing the medicines will impede the market expansion in the foreseeable future.

North America To Make Notable Contributions Towards Overall Market Share By 2026

The growth of the market in the region over the estimated timeline is subject to growing use of anti-cancer drug therapies in the countries like the U.S. and Canada. In addition to this, presence of strong healthcare infrastructure and number of non-government institutes providing cancer management services will proliferate the regional market growth. Apparently, huge occurrence of the chronic ailments and unhealthy diet as well as disorganized lifestyle along with lack of time management and busy lifestyle or hectic work will increase the demand for the product in the healthcare sector across the region in the near future.

Key players influencing the market growth include Merck & Co., Inc.; Teva pharmaceutical Industries Ltd.; Genentech, Inc.; Amgen Inc.; Pfizer Inc.; Bristol-Myers Squibb Company; Accord Healthcare, Inc.; Baxter Healthcare Corporation; Aspen Global Inc.; Boehringer Ingelheim GmbH; Bayer AG; Hoffmann-La Roche Ltd.; Johnson & Johnson Pvt. Ltd.; Lundbeck LLC; and AbbVie Inc.

The global anti-neoplastic agents market is segmented as follows:

By product type:

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Hormonal Therapy (Biologic Therapy)
  • Others

By end-users/application:

  • Blood cancer
  • Breast cancer
  • Gastrointestinal cancer
  • Prostate cancer
  • Respiratory/lung cancer
  • Other cancers

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodulogy
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodulogy
  • Chapter 2. Executive Summary
    • 2.1. Anti-Neoplastic Agents Market, 2016–2026 (USD Billion)
    • 2.2. Anti-Neoplastic Agents Market: Snapshot
  • Chapter 3. Global Anti-Neoplastic Agents Market– Industry Analysis
    • 3.1. Anti-Neoplastic Agents Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Breakthroughs in the personalized medicine domain are predicted to offer new growth avenues for the anti-neoplastic agents industry over the forecast timeline.
      • 3.2.2. These drugs are utilized in combination with other drug treatments in radiotherapies, surgeries, hormone therapies, and other various targeted therapies and this will drive the market trends.
    • 3.3. Porter’s Five Forces Analysis
    • 3.4. Market Attractiveness Analysis
      • 3.4.1. Market attractiveness analysis By Product
      • 3.4.2. Market attractiveness analysis By End-Users/ Application
  • Chapter 4. Global Anti-Neoplastic Agents Market– Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Anti-Neoplastic Agents Market: company market share, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Product launches
      • 4.2.3. Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Anti-Neoplastic Agents Market– Product Analysis
    • 5.1. Global Anti-Neoplastic Agents Market overview: By Product
      • 5.1.1. Global Anti-Neoplastic Agents Market Share, By Product, 2019 and 2026
    • 5.2. Targeted Therapy
      • 5.2.1. Global Anti-Neoplastic Agents Market by Targeted Therapy, 2016–2026 (USD Billion)
    • 5.3. Chemotherapy
      • 5.3.1. Global Anti-Neoplastic Agents Market by Chemotherapy, 2016–2026 (USD Billion)
    • 5.4. Hormonal Therapy
      • 5.4.1. Global Anti-Neoplastic Agents Market by Hormonal Therapy , 2016–2026 (USD Billion)
    • 5.5. Immunotherapy
      • 5.5.1. Global Anti-Neoplastic Agents Market by Immunotherapy , 2016–2026 (USD Billion)
    • 5.6. Others
      • 5.6.1. Global Anti-Neoplastic Agents Market by Others, 2016–2026 (USD Billion)
  • Chapter 6. Global Anti-Neoplastic Agents Market– End-Users/ Application Analysis
    • 6.1. Global Anti-Neoplastic Agents Market overview: By End-Users/ Application
      • 6.1.1. Global Anti-Neoplastic Agents Market Share, By End-Users/ Application, 2019 and 2026
    • 6.2. Breast Cancer
      • 6.2.1. Global Anti-Neoplastic Agents Market by Breast Cancer , 2016–2026 (USD Billion)
    • 6.3. Blood Cancer
      • 6.3.1. Global Anti-Neoplastic Agents Market by Blood Cancer, 2016–2026 (USD Billion)
    • 6.4. Prostate Cancer
      • 6.4.1. Global Anti-Neoplastic Agents Market by Prostate Cancer, 2016–2026 (USD Billion)
    • 6.5. Gastrointestinal Cancer
      • 6.5.1. Global Anti-Neoplastic Agents Market by Gastrointestinal Cancer, 2016–2026 (USD Billion)
    • 6.6. Respiratory/Lung Cancer
      • 6.6.1. Global Anti-Neoplastic Agents Market by Respiratory/Lung Cancer, 2016–2026 (USD Billion)
    • 6.7. Other Cancers
      • 6.7.1. Global Anti-Neoplastic Agents Market by Other Cancers, 2016–2026 (USD Billion)
  • Chapter 7. Company Profiles
    • 7.1. Teva pharmaceutical Industries Ltd.
      • 7.1.1. Overview
      • 7.1.2. Financials
      • 7.1.3. Product Portfulio
      • 7.1.4. Business Strategy
      • 7.1.5. Recent Developments
    • 7.2. Amgen Inc.
      • 7.2.1. Overview
      • 7.2.2. Financials
      • 7.2.3. Product Portfulio
      • 7.2.4. Business Strategy
      • 7.2.5. Recent Developments
    • 7.3. Hoffmann-La Roche Ltd.
      • 7.3.1. Overview
      • 7.3.2. Financials
      • 7.3.3. Product Portfulio
      • 7.3.4. Business Strategy
      • 7.3.5. Recent Developments
    • 7.4. Bristul-Myers Squibb Company
      • 7.4.1. Overview
      • 7.4.2. Financials
      • 7.4.3. Product Portfulio
      • 7.4.4. Business Strategy
      • 7.4.5. Recent Developments
    • 7.5. Aspen Global Inc.
      • 7.5.1. Overview
      • 7.5.2. Financials
      • 7.5.3. Product Portfulio
      • 7.5.4. Business Strategy
      • 7.5.5. Recent Development
    • 7.6. Boehringer Ingelheim GmbH
      • 7.6.1. Overview
      • 7.6.2. Financials
      • 7.6.3. Product Portfulio
      • 7.6.4. Business Strategy
      • 7.6.5. Recent Development
    • 7.7. Bayer AG
      • 7.7.1. Overview
      • 7.7.2. Financials
      • 7.7.3. Product Portfulio
      • 7.7.4. Business Strategy
      • 7.7.5. Recent Development
    • 7.8. Merc & Co., Inc.
      • 7.8.1. Overview
      • 7.8.2. Financials
      • 7.8.3. Product Portfulio
      • 7.8.4. Business Strategy
      • 7.8.5. Recent Development
    • 7.9. Johnson & Johnson Pvt. Ltd.
      • 7.9.1. Overview
      • 7.9.2. Financials
      • 7.9.3. Product Portfulio
      • 7.9.4. Business Strategy
      • 7.9.5. Recent Development
    • 7.10. Baxter Healthcare Corporation
      • 7.10.1. Overview
      • 7.10.2. Financials
      • 7.10.3. Product Portfulio
      • 7.10.4. Business Strategy
      • 7.10.5. Recent Development
    • 7.11. Accord Healthcare, Inc.
      • 7.11.1. Overview
      • 7.11.2. Financials
      • 7.11.3. Product Portfulio
      • 7.11.4. Business Strategy
      • 7.11.5. Recent Development
    • 7.12. Pfizer Inc.
      • 7.12.1. Overview
      • 7.12.2. Financials
      • 7.12.3. Product Portfulio
      • 7.12.4. Business Strategy
      • 7.12.5. Recent Development
    • 7.13. Lundbeck LLC
      • 7.13.1. Overview
      • 7.13.2. Financials
      • 7.13.3. Product Portfulio
      • 7.13.4. Business Strategy
      • 7.13.5. Recent Development
    • 7.14. Genentech, Inc.
      • 7.14.1. Overview
      • 7.14.2. Financials
      • 7.14.3. Product Portfulio
      • 7.14.4. Business Strategy
      • 7.14.5. Recent Development
    • 7.15. AbbVie Inc.
      • 7.15.1. Overview
      • 7.15.2. Financials
      • 7.15.3. Product Portfulio
      • 7.15.4. Business Strategy
      • 7.15.5. Recent Development

Methodology


Frequently Asked Questions

The growth of the market over the estimated timespan is attributed to growing cases of cancer along with demand for cost-efficient therapies. Breakthroughs in the personalized medicine domain are predicted to offer new growth avenues for the anti-neoplastic agents industry over the forecast timeline. These drugs are utilized in combination with other drug treatments in radiotherapies, surgeries, hormone therapies, and other various targeted therapies and this will drive the market trends.

According to Zion Market Research Report, the global Anti-Neoplastic Agents market, which was estimated at 110(USD Billion) in 2019 and projected to hit revenue of nearly 165.78 (USD Billion) by 2026, is set to record a CAGR of nearly 8% over 2020-2026.

North America is likely to make noteworthy contributions towards overall market revenue. The growth of the regional market over the estimated timespan is attributed to growing use of anti-cancer drug therapies in the countries like the U.S. and Canada. In addition to this, presence of strong healthcare infrastructure and number of non-government institutes providing cancer management services will proliferate the regional market growth. Apparently, huge occurrence of the chronic ailments and unhealthy diet as well as disorganized lifestyle along with lack of time management and busy lifestyle or hectic work will increase the demand for the product in the healthcare sector across the region in the near future.

The key players profiled in the report include Merck & Co., Inc.; Teva pharmaceutical Industries Ltd.; Genentech, Inc.; Amgen Inc.; Pfizer Inc.; Bristol-Myers Squibb Company; Accord Healthcare, Inc.; Baxter Healthcare Corporation; Aspen Global Inc.; Boehringer Ingelheim GmbH; Bayer AG; Hoffmann-La Roche Ltd.; Johnson & Johnson Pvt. Ltd.; Lundbeck LLC; and AbbVie Inc.

Choose License Type

Request the coronavirus impact analysis across industries and markets

HappyClients

Office Address

Corporate Office

Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Are On Social